<DOC>
	<DOCNO>NCT01863680</DOCNO>
	<brief_summary>The primary objective trial demonstrate non-inferiority clinical pregnancy rate per embryo transfer historical standard value in-vitro fertilization ( IVF ) /embryo transfer ( ET ) cycle Japan ( Japan Society Obstetrics Gynecology [ JSOG ] 2009 registry data : 24.3 percent [ % ] ) . The secondary objective trial assess biochemical pregnancy rate per ET , pharmacokinetics , safety COL-1620 .</brief_summary>
	<brief_title>Phase 3 Trial Evaluate Efficacy Safety COL-1620 Vaginal Progesterone Gel</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>Japanese race Woman history infertility Invitro fertilization embryo transfer ( IVF/ET ) indicate The controlled ovarian stimulation ( COS ) therapy gonadotropinreleasing hormone ( GnRH ) analogue ( agonist antagonist ) combination folliclestimulating hormone ( FSH ) contain preparation Healthy premenopausal woman age 20 45 year ( inclusive ) wish conceive Body mass index ( BMI ) 17.0 25.0 kilogram per square meter ( kg/m^2 ) ( inclusive ) A negative pregnancy test ( urinary betahuman chorionic gonadotropin [ hCG ] ) prior start COS Normal cervical smear result ( Papanicolaou [ PAP ] test : Negative Intraepithelial Lesion Malignancy [ NILM ] [ Atypical Squamous Cells Undetermined Significance { ASCUS } Human Papillomavirus { HPV } negative ] ) within 12 month prior date informed consent . If available , cervical smear HPV test perform part Screening No clinically significant abnormal finding screen hematology , biochemistry urinalysis parameter Full comprehension study voluntary write informed consent obtain write prior trialrelated activity History recurrent pregnancy loss ( define 3 previous spontaneous abortion ) History 3 consecutive cancel fail ( clinical pregnancy ) IVF/ET cycle Abnormal hemorrhage reproductive tract undetermined origin Any contraindication pregnant and/or carry pregnancy term ( example , malformation sexual organ fibroid tumor uterus incompatible pregnancy ) Uterine myoma require treatment Extrauterine pregnancy within last 3 month prior date informed consent History presence intracranial tumor ( example , hypothalamic pituitary tumor ) Presence suspect gonadotropin estrogendependent malignancy ( example , ovarian , uterine mammary carcinoma ) Ovarian enlargement cyst unknown etiology Breastfeeding lactation History severe Ovarian Hyperstimulation Syndrome ( OHSS ) ( Classification OHSS Severity , per Japan Reproductive/Endocrine Working Group ) Known Human Immunodeficiency Virus ( HIV ) positive status , history current active infection Hepatitis B C Known allergy hypersensitivity progesterone preparation gonadotropin preparation and/or excipients , contraindication receive medication control ovarian stimulation ( example , gonadotropin , GnRH analogues , combine oral contraceptive pill , appropriate ) History suspect alcohol substance abuse within 5 year prior date informed consent Clinically significant systemic disease ( example , insulindependent diabetes , epilepsy , severe migraine , acute porphyria , hepatic , renal cardiovascular disease , severe corticosteroiddependent asthma ) Active thrombophlebitis , thromboembolic disorder cerebral apoplexy , history condition Other significant disease Investigator 's SubInvestigator 's opinion would exclude subject trial Participation another clinical trial within 3 month prior date informed consent simultaneous participation another clinical trial Legal incapacity limit legal capacity</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Infertility</keyword>
	<keyword>COL-1620</keyword>
	<keyword>progesterone gel</keyword>
	<keyword>Fertilization Vitro</keyword>
	<keyword>Embryo Transfer</keyword>
</DOC>